BK

Biju Kapplingattu Krishnan Namboodiri

Active Director Whole-Time Director DIN 02234729
DIN 02234729 First appointment Mar 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 2 active board seats
Past companies 2 historical roles
Total affiliations 4 Since Mar 2009
Shareholding value •••• Premium profile

About Biju Kapplingattu Krishnan Namboodiri

Data last updated:

Biju Kapplingattu Krishnan Namboodiri is a Whole-Time Director at Fling Pharmaceuticals Private Limited (since 2009) and Director at Albus Pharmaceuticals Private Limited (since 2012). The companies operate in Pharma, Trading and Food and Beverages. The 2 current companies with reported revenue have a combined latest revenue of ₹15.09 Cr; the largest is Fling Pharmaceuticals Private Limited at ₹14.10 Cr (FY 2024). Earlier, Biju Kapplingattu Krishnan Namboodiri was a Director at Wellness Diet Private Limited (2023–2024) and Whole-Time Director at Ave Health Care Private Limited (2020–2024).

DIN 02234729
Primary Designation Whole-Time Director
Industry Pharma
First Appointment 11 Mar 2009
Oldest Company Age 23 yrs
Largest company Fling Pharmaceuticals Private Limited · ₹14.10 Cr (FY 2024)
Combined revenue ₹15.09 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Whole-Time Director11 Mar 20092005₹14.10 Cr (FY 2024)Active
Director21 Mar 20122003₹98.8 Lakh (FY 2025)Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Wellness Diet Private Limited U15497KL2010PTC060236
Director30 Apr 20232010₹4.90 Cr (FY 2024)Active
Ave Health Care Private Limited U24239KL2003PTC016619
Whole-Time Director06 Jul 20202003₹18.4 Lakh (FY 2017)Active

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Biju Kapplingattu Krishnan Namboodiri

Directorship timeline

Open interactive timeline →
Albus Pharmaceuticals Private Limited
Fling Pharmaceuticals Private Limited
Wellness Diet Private Limited
Ave Health Care Private Limited
Premium access

Shareholding and investment profile for Biju Kapplingattu Krishnan Namboodiri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Biju Kapplingattu Krishnan Namboodiri

Biju Kapplingattu Krishnan Namboodiri currently holds 2 directorships: Fling Pharmaceuticals Private Limited (Whole-Time Director, since 11 Mar 2009, revenue ₹14.10 Cr (FY 2024)); Albus Pharmaceuticals Private Limited (Director, since 21 Mar 2012, revenue ₹98.8 Lakh (FY 2025)).

Biju Kapplingattu Krishnan Namboodiri was first appointed on 11 Mar 2009 as Whole-Time Director at Fling Pharmaceuticals Private Limited. The most recent appointment on record is 30 Apr 2023 at Wellness Diet Private Limited.

The 2 current companies of Biju Kapplingattu Krishnan Namboodiri that report revenue have a combined latest revenue of ₹15.09 Cr: Fling Pharmaceuticals Private Limited ₹14.10 Cr (FY 2024); Albus Pharmaceuticals Private Limited ₹98.8 Lakh (FY 2025).

Biju Kapplingattu Krishnan Namboodiri held 2 earlier board appointments: Wellness Diet Private Limited (Director, 30 Apr 2023 to 28 Feb 2024); Ave Health Care Private Limited (Whole-Time Director, 06 Jul 2020 to 28 Feb 2024).

The current boards of Biju Kapplingattu Krishnan Namboodiri's companies include David Joseph Palayoor (Fling Pharmaceuticals Private Limited), Madhu Karuvanchery Vijayan Nair (Fling Pharmaceuticals Private Limited), Latha Kattumadam Narayanan Namboodiripad (Albus Pharmaceuticals Private Limited), Rathibai Vallath Paragodan (Albus Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available